Company profile: Cellectis
1.1 - Company Overview
Company description
- Provider of adoptive cancer immunotherapies, developing allogeneic CAR T candidates including UCART22 for r/r B-ALL, UCART123 targeting CD123 for AML, and UCART20x22 targeting CD20/CD22 for B-cell malignancies, plus TALEN gene editing and PulseAgile electroporation technologies.
Products and services
- UCART20x22: Cellectis' first allogeneic dual CAR T-cell product candidate (dual-CAR), engineered to treat B-cell malignancies by targeting CD20 and CD22
- TALEN®: A gene editing technology (gene-editing) that enables precise modification of DNA for the development of therapeutics
- UCART123: An allogeneic CAR T-cell product candidate (allogeneic) targeting CD123 for the treatment of acute myeloid leukemia (AML)
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Cellectis
Tokai Pharmaceuticals
HQ: United States
Website
- Description: Provider of cancer therapies, focused on developing and delivering treatments for patients living with cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tokai Pharmaceuticals company profile →
Theraclion
HQ: France
Website
- Description: Provider of high-intensity focused ultrasound (HIFU) echotherapy medical equipment, combining HIFU with standard ultrasound for non-invasive treatment and target localization. Solutions include SONOVEIN for varicose veins; ECHOPULSE for thyroid nodules and breast fibroadenoma; CURE-OP for combinational cancer therapy integrating ultrasound with radiotherapy; and EPack single-use disposables for cooling and coupling.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Theraclion company profile →
iOmx Therapeutics
HQ: Germany
Website
- Description: Provider of first-in-class cancer immunotherapies and discovery platforms targeting novel immune checkpoint modulators on tumor cells. Offerings include iOTargTM, a high-throughput genetic screening platform to identify checkpoint molecules; OMX-0407, an oral spectrum-selective SIK inhibitor in first-in-human trials; and IOMX-0675, a dual LILRB1/LILRB2 antibody to re-activate innate and adaptive immunity.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full iOmx Therapeutics company profile →
Insure One
HQ: United States
Website
- Description: Provider of at-home fecal immunochemical tests (FIT) for colorectal cancer screening, using a non-invasive brush-based sample collection to detect lower gastrointestinal bleeding without direct stool handling, with a focus on patient compliance and data privacy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Insure One company profile →
RefleXion
HQ: United States
Website
- Description: Provider of biologically-guided radiotherapy systems for patients with cancer, offering SCINTIX therapy that uses emissions from cancer cells to target and treat lung or bone tumors at any stage. Provides the RefleXion X1 platform delivering SCINTIX and CT-guided IMRT and SBRT with fan-beam kVCT imaging for superior patient localization, plus Limbus Contour integration to expedite radiotherapy planning.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full RefleXion company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Cellectis
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Cellectis
2.2 - Growth funds investing in similar companies to Cellectis
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Cellectis
4.2 - Public trading comparable groups for Cellectis
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →